Linked Life Data

11258401

Source:http://linkedlifedata.com/resource/pubmed/id/11258401

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-3-21
pubmed:abstractText
Imaging of dopamine transporters (DATs) in the brain using [99Tcm]TRODAT-1 showed excellent pharmacokinetics for estimation of transporter concentrations. It has been reported that there may be differences in the binding kinetics of DAT radiotracers to DATs between normal subjects and patients with Parkinson's disease (PD). The aim of this study was to determine an optimal time point for (99Tcm]TRODAT-1 brain single photon emission tomography (SPET) acquisition that provides stable target to non-target ratios reflecting the DAT concentration in the brain. Serial [99Tcm]TRODAT-1 brain SPET images 2, 3 and 4 h after intravenous injection of [99Tcm]TRODAT-1 (925 MBq) were performed in five healthy subjects and nine PD patients. Regions of interests were drawn, and caudate/occipital (C/O) and putamen/occipital (P/O) specific to non-specific [99Tcm]TRODAT-1 binding ratios were calculated. The C/O and P/O ratios in healthy subjects showed consistent increases with time, but in PD patients, the C/O and P/O ratios of [99Tcm]TRODAT-1 reached a stable level at 3 h post-injection. There was a statistically significant difference (P < 0.001) between PD and normal subjects at 4 h post-injection for both the C/O and the P/O ratios. In conclusion, we recommend the acquisition of [99Tcm]TRODAT-1 SPET images at 4 h post-injection, as at this time point the C/O and P/O ratios can be used to discriminate between PD patients and healthy subjects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0143-3636
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
151-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11258401-Aged, pubmed-meshheading:11258401-Basal Ganglia, pubmed-meshheading:11258401-Carrier Proteins, pubmed-meshheading:11258401-Dopamine Plasma Membrane Transport Proteins, pubmed-meshheading:11258401-Female, pubmed-meshheading:11258401-Humans, pubmed-meshheading:11258401-Image Processing, Computer-Assisted, pubmed-meshheading:11258401-Injections, Intravenous, pubmed-meshheading:11258401-Male, pubmed-meshheading:11258401-Membrane Glycoproteins, pubmed-meshheading:11258401-Membrane Transport Proteins, pubmed-meshheading:11258401-Middle Aged, pubmed-meshheading:11258401-Nerve Tissue Proteins, pubmed-meshheading:11258401-Organotechnetium Compounds, pubmed-meshheading:11258401-Parkinson Disease, pubmed-meshheading:11258401-Radiopharmaceuticals, pubmed-meshheading:11258401-Tomography, Emission-Computed, Single-Photon, pubmed-meshheading:11258401-Tropanes
pubmed:year
2001
pubmed:articleTitle
The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease.
pubmed:affiliation
Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan. kaopanfu@adm.cgmh.org.tw
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't